China Pharma (CPHI) Ran 790% in a Day on $168,000 of Cash. The Float Math Is the Whole Story. Here's the Distribution.

On Tuesday, July 21, shares of China Pharma Holdings (NYSE American: CPHI) closed at $8.10. The day before, they closed at $0.91. That is a one-session move of roughly 790% — and intraday, the stock printed as high as $19.19, a level it had not seen in years.

More than 88.3 million shares changed hands on the day. The company has 40,522,002 shares outstanding in total. In other words, the entire share count turned over more than twice in a single session. By Wednesday morning it was the most-trended pharmaceutical ticker on retail stream after retail stream, and the after-hours tape added another leg on top.

Here is the problem, and the reason this briefing exists: there was no clear catalyst. No FDA decision. No partnership. No earnings surprise. No contract. A company most investors had never heard of, headquartered in Haikou on the Chinese island of Hainan, went vertical on volume — and tens of thousands of people are now holding it, or thinking about holding it, without a single structured look at what they actually own.

So let's do the work the stream won't. Not a call. Not a target. Just the filings, the float, and the arithmetic.

What China Pharma actually is

China Pharma Holdings is a specialty pharmaceutical company that develops and sells generic and branded medications and some traditional Chinese medicine products, manufactured through its subsidiary in Hainan Province. It is a real operating business with a real factory — this is not a pure shell.

But the corporate lineage is worth knowing before you assign it a $328 million valuation, which is roughly what Tuesday's close implies (40.5 million shares × $8.10). The entity now called China Pharma Holdings has, over its life on the public market, previously carried the names Kilkenny Acquisition Corp, Softstone Inc., and TS Electronics, Inc. before becoming a China-based pharmaceutical company through a reverse merger. That is the classic path of a micro-cap that reached U.S. markets through the back door rather than a conventional IPO.

None of that is disqualifying on its own. What matters is what the most recent numbers say — and the most recent numbers, filed with the SEC six weeks ago, tell a very specific story.

The number that frames everything: $168,474

China Pharma's most recent quarterly report (Form 10-Q for the period ended March 31, 2026, filed May 15) lists cash and cash equivalents of $168,474.

Not $168 million. Not $168 thousand times some multiple. One hundred sixty-eight thousand dollars — down from $345,112 at the end of 2025. That is the entire liquid cash position of a company the market just decided is worth a third of a billion dollars.

For the quarter, China Pharma reported:

• Revenue of $983,536 — under a million dollars, and down from $1,136,287 in the same quarter a year earlier
• A net loss of $1,143,148
• General and administrative expenses of $1,226,272 — more than double the year-ago figure, and larger than the entire quarter's revenue

A company losing more than a million dollars a quarter, with revenue shrinking and $168,474 in the bank, is a company with a countdown clock. And that clock is the single most important thing about this stock — more important than the chart, more important than the momentum, more important than whatever is being posted about it on the stream right now.

Because there is a very well-worn playbook for what a cash-starved micro-cap does when its stock suddenly trades 88 million shares in a day. And whether or not China Pharma runs that playbook is the entire question the price is asking.

So here is the question this briefing answers: when a company with $168,000 of cash and an effective shelf registration watches its own stock go up 790% on no news, what happens next — and where do the realistic price scenarios actually land?

The rest of this briefing is for paid members: the exact dilution mechanics and share-count history, the shelf-registration capacity that lets management sell into this spike, the intangible-asset question mark that now makes up 86% of the balance sheet, the reverse-split lineage, and three scenario-by-scenario price zones — with the arithmetic behind each.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →